Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro

Tyrosine kinase inhibitors (TKIs), such as imatinib (IMA) and nilotinib (NIL), are the cornerstone of chronic myeloid leukemia (CML) treatment via the blockade of the oncogenic BCR-ABL1 fusion protein. However, skeletal side effects are commonly observed in pediatric patients receiving long-term tre...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncol Lett
Egile Nagusiak: Kroschwald, Lysann Michaela, Tauer, Josephine Tabea, Kroschwald, Sonja Ingrid, Suttorp, Meinolf, Wiedenfeld, Anne, Beissert, Stefan, Bauer, Andrea, Rauner, Martina
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: D.A. Spandidos 2019
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6614669/
https://ncbi.nlm.nih.gov/pubmed/31423283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.10518
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak